TY - JOUR
T1 - Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma
T2 - Samarium-153- EDTMP and Radium-223
AU - Anderson, Peter M.
AU - Subbiah, Vivek
AU - Rohren, Eric
N1 - Publisher Copyright:
© Springer International Publishing Switzerland 2014.
PY - 2014
Y1 - 2014
N2 - Osteosarcoma is a cancer characterized by formation of bone by malignant cells. Routine bone scan imaging with Tc-99m-MDP is done at diagnosis to evaluate primary tumor uptake and check for bone metastases. At time of relapse the Tc-99m-MDP bone scan also provides a specifi c means to assess formation of bone by malignant osteosarcoma cells and the potential for bone-seeking radiopharma-ceuticals to deliver radioactivity directly into osteoblastic osteosarcoma lesions. This chapter will review and compare a bone-seeking radiopharmaceutical that emits beta-particles, samarium-153-EDTMP, with an alpha-particle emitter, radium-223. The charged alpha particles from radium-223 have far more mass and energy than beta particles (electrons) from Sm-153-EDTMP. Because radium-223 has less marrow toxicity and more radiobiological effectiveness, especially if inside the bone forming cancer cell than samarium-153-EDTMP, radium-223 may have greater potential to become widely used against osteosarcoma as a targeted therapy. Radium-223 also has more potential to be used with chemotherapy against osteosar-coma and bone metastases. Because osteosarcoma makes bone and radium-223 acts like calcium, this radiopharmaceutical could possibly become a new targeted means to achieve safe and effective reduction of tumor burden as well as facilitate better surgery and/or radiotherapy for diffi cult to resect large, or metastatic tumors.
AB - Osteosarcoma is a cancer characterized by formation of bone by malignant cells. Routine bone scan imaging with Tc-99m-MDP is done at diagnosis to evaluate primary tumor uptake and check for bone metastases. At time of relapse the Tc-99m-MDP bone scan also provides a specifi c means to assess formation of bone by malignant osteosarcoma cells and the potential for bone-seeking radiopharma-ceuticals to deliver radioactivity directly into osteoblastic osteosarcoma lesions. This chapter will review and compare a bone-seeking radiopharmaceutical that emits beta-particles, samarium-153-EDTMP, with an alpha-particle emitter, radium-223. The charged alpha particles from radium-223 have far more mass and energy than beta particles (electrons) from Sm-153-EDTMP. Because radium-223 has less marrow toxicity and more radiobiological effectiveness, especially if inside the bone forming cancer cell than samarium-153-EDTMP, radium-223 may have greater potential to become widely used against osteosarcoma as a targeted therapy. Radium-223 also has more potential to be used with chemotherapy against osteosar-coma and bone metastases. Because osteosarcoma makes bone and radium-223 acts like calcium, this radiopharmaceutical could possibly become a new targeted means to achieve safe and effective reduction of tumor burden as well as facilitate better surgery and/or radiotherapy for diffi cult to resect large, or metastatic tumors.
KW - Beta particle
KW - Bone scan for screening
KW - Double strand DNA breaks
KW - Internal radiotherapy
KW - Osteosarcoma
KW - Radiobiological effectiveness (RBE)
KW - Radium-223
KW - Resistance is futile
KW - Samarium-153
KW - Alpha particle
UR - http://www.scopus.com/inward/record.url?scp=84907164048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907164048&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-04843-7_16
DO - 10.1007/978-3-319-04843-7_16
M3 - Article
C2 - 24924181
AN - SCOPUS:84907164048
SN - 0065-2598
VL - 804
SP - 291
EP - 304
JO - Advances in experimental medicine and biology
JF - Advances in experimental medicine and biology
ER -